Last Updated on January 3, 2024 by The Health Master
Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a voluntary recall of 13 lots (listed below) of oral Orphenadrine Citrate 100 mg Extended Release (ER) Tablets to the consumer level.
The presence of a nitrosamine (N-methyl-N-nitroso-2-[(2-methylphenyl) phenylmethoxy] ethanamine (NMOA or Nitroso-Orphenadrine)) impurity, which has the potential to be above the U.S. Food and Drug Administration (USFDA)’s Acceptable Daily Intake (ADI) limit of 26.5 ng/day, was detected in the lots during recent testing.
These 13 lots of Orphenadrine Citrate ER Tablets were shipped to customers from August 2019 to April 2021.
Nitrosamines are substances with carcinogenic potency (substances that could cause cancer) when present above the allowable exposure limits.
While the use of product belonging to the recalled lots may represent a risk to patients, to date, Sandoz has not received any reports of adverse events related to the presence of a nitrosamine impurity in the lot.
Orphenadrine Citrate ER Tablets are used as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. The product is packaged in 100-count and 1000-count bottles and was distributed nationwide in the USA to wholesalers and distributors.
| Product Name | NDC Number | Lot Number | Expiration Date | Date of Manufacture |
|---|---|---|---|---|
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | JX6411 | 05/2022 | 5/24/2019 |
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | JX6413 | 05/2022 | 5/24/2019 |
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | KC0723 | 08/2022 | 8/21/2019 |
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | KC3303 | 08/2022 | 8/21/2019 |
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | KE4348 | 11/2022 | 11/6/2019 |
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | KE7169 | 11/2022 | 11/6/2019 |
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | KE4349 | 11/2022 | 11/6/2019 |
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | KL3199 | 03/2023 | 3/3/2020 |
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | KM0072 | 03/2023 | 3/3/2020 |
| Orphenadrine Citrate ER Tablets | 0185-0022-10 | KS3939+ | 03/2023 | 3/3/2020 |
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | LA7704 | 10/2023 | 10/6/2020 |
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | LA7703 | 10/2023 | 10/6/2020 |
| Orphenadrine Citrate ER Tablets | 0185-0022-01 | LA9243 | 11/2023 | 11/18/2020 |
+ 1,000-count bottle
This recall of Orphenadrine Citrate ER Tablets is specific to the lots listed above and does not apply to any other strengths of Sandoz Orphenadrine Citrate ER Tablets nor to other lot numbers of the product. Any product returned that is not associated with this recall will be destroyed, and no credit will be issued.
Sandoz is notifying its wholesalers and distributors by mail and is arranging for the return of all recalled product. Wholesalers and distributors that have Orphenadrine Citrate ER Tablets subject to this recall should immediately stop distribution of the recalled product and quarantine and return all recalled product in their inventory.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Drug recall: This drug recalled due to detection of NDMA
Drug recall: Some lots of Blood Pressure Drug due to this reason
Drug recall: Fresenius Kabi recalled Sodium Acetate Injection, USP Due to this reason
Drug recall: Macleods recalls products for these manufacturing issues
Drug recall: Aurobindo, Sun Pharma recall these products
Drug recall: Medical Device – Infusion Pumps recalled due to this reason
NPPA updated price lists: Download
NPPA allows price hike of Essential Medicines by more than 10 percent
WHO establishes Global Centre for Traditional Medicine in India
Maharashtra FDA to get 15 new Asstt. Commissioners to combat impending…
USFDA probe of Abbott facility finds quality control issues
DCGI calls on stakeholders to initiate Clinical Trials early
USFDA gives nod to Lupin for Sildenafil for oral suspension
NPPA’s expert panel recommends retail price for FDCs of anti-diabetic linagliptin
DCGI gives nod to Phase-3 Clinical Trial of Covovax Vaccine
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
